Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine ...

GSK is set to buy Rapt Therapeutics in a $2.2 billion deal. AstraZeneca agreed to a $630 million pact to secure remaining rights to armored CAR-T from AbelZeta. Bristol Myers Squibb signed a deal with ...

GreenWay Tanasi, LLC, the consumer wellness company behind the Tanasitm brand, today announced that the proprietary 1:1 cannabidiol (CBD) and cannabidiolic acid (CBDA) formulation used across its ...

ETHealthworld.com brings latest takeda pharmaceutical news, views and updates from all top sources for the Indian Health industry.

The National Certification Corporation (NCC) is pleased to announce the appointment of Cynthia F. Krening, MS, RNC-OB, C-EFM, FAWHONN as President of NCC. Directors are elected by constituents through ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to ...

The new generic drug has been approved for treatment of bovine respiratory disease and associated pyrexia in beef and ...